Amantadine and other antiglutamate agents
Identifieur interne : 004577 ( Main/Exploration ); précédent : 004576; suivant : 004578Amantadine and other antiglutamate agents
Auteurs :Source :
- Movement Disorders [ 0885-3185 ] ; 2002-07.
English descriptors
- KwdEn :
- Amantadine (adverse effects), Amantadine (pharmacology), Amantadine (therapeutic use), Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Glutamic Acid (metabolism), Humans, Parkinson Disease (drug therapy), Psychomotor Performance (drug effects), Randomized Controlled Trials as Topic.
- MESH :
- chemical , adverse effects : Amantadine, Antiparkinson Agents.
- chemical , metabolism : Glutamic Acid.
- chemical , pharmacology : Amantadine, Antiparkinson Agents.
- chemical , therapeutic use : Amantadine, Antiparkinson Agents.
- drug effects : Psychomotor Performance.
- drug therapy : Parkinson Disease.
- Humans, Randomized Controlled Trials as Topic.
Url:
DOI: 10.1002/mds.5557
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001D17
- to stream Istex, to step Curation: 001D17
- to stream Istex, to step Checkpoint: 002E69
- to stream PubMed, to step Corpus: 003988
- to stream PubMed, to step Curation: 003988
- to stream PubMed, to step Checkpoint: 003B98
- to stream Ncbi, to step Merge: 000863
- to stream Ncbi, to step Curation: 000863
- to stream Ncbi, to step Checkpoint: 000863
- to stream Main, to step Merge: 006583
- to stream Main, to step Curation: 004577
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Amantadine and other antiglutamate agents</title>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CB380C7FA45B4FD17E4ACDB7FD6746F47BE89A12</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1002/mds.5557</idno>
<idno type="url">https://api.istex.fr/document/CB380C7FA45B4FD17E4ACDB7FD6746F47BE89A12/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001D17</idno>
<idno type="wicri:Area/Istex/Curation">001D17</idno>
<idno type="wicri:Area/Istex/Checkpoint">002E69</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12211136</idno>
<idno type="wicri:Area/PubMed/Corpus">003988</idno>
<idno type="wicri:Area/PubMed/Curation">003988</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003B98</idno>
<idno type="wicri:Area/Ncbi/Merge">000863</idno>
<idno type="wicri:Area/Ncbi/Curation">000863</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000863</idno>
<idno type="wicri:Area/Main/Merge">006583</idno>
<idno type="wicri:Area/Main/Curation">004577</idno>
<idno type="wicri:Area/Main/Exploration">004577</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Amantadine and other antiglutamate agents</title>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2002-07">2002-07</date>
<biblScope unit="vol">17</biblScope>
<biblScope unit="issue">S4</biblScope>
<biblScope unit="supplement">4</biblScope>
<biblScope unit="page" from="S13">S13</biblScope>
<biblScope unit="page" to="S22">S22</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">CB380C7FA45B4FD17E4ACDB7FD6746F47BE89A12</idno>
<idno type="DOI">10.1002/mds.5557</idno>
<idno type="ArticleID">MDS5557</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine (adverse effects)</term>
<term>Amantadine (pharmacology)</term>
<term>Amantadine (therapeutic use)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Glutamic Acid (metabolism)</term>
<term>Humans</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Psychomotor Performance (drug effects)</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Amantadine</term>
<term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Glutamic Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amantadine</term>
<term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term>
<term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Psychomotor Performance</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list></list>
<tree></tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004577 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004577 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:CB380C7FA45B4FD17E4ACDB7FD6746F47BE89A12 |texte= Amantadine and other antiglutamate agents }}
This area was generated with Dilib version V0.6.23. |